Just days after announcing that it had received a $205 million federal contract to provide COVID-19 InteliSwab tests, Bethlehem’s OraSure said the Biomedical Advanced Research Development Authority (BARDA) will provide up to $13.6 million in funding for the Company to obtain 510(k) clearance and CLIA waiver for their COVID-19 rapid test, InteliSwab, from the Food & Drug Administration.
User ID / Email / Password is case sensitive
To inquire about group subscriptions or an enterprise site license for your organization, contact Tracy Bumba
Get Essential Business News
1 Year Print & Digital
1 Year Print +Digital + Data Joe (BOL)
Monthly Digital Only
First time registering your paid subscription? Click here
Having trouble with login?
Please contact email@example.com.